Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
11:51am, Friday, 10'th Jan 2025
AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.
MoneyShow's Best Investment Ideas For 2025: Part 2
09:30am, Friday, 10'th Jan 2025
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur
Abbvie to record $3.5 bln charge related to schizophrenia drug
08:44am, Friday, 10'th Jan 2025
Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
AbbVie's Stock Is Unfairly Cheap
09:35am, Thursday, 09'th Jan 2025
AbbVie's Stock Is Unfairly Cheap
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 09'th Jan 2025
NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Tuesday, 07'th Jan 2025
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
08:00am, Tuesday, 07'th Jan 2025
Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment† IRVINE, Calif. , Jan. 7, 2025 /PRNewswire/ -- Alle
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
07:55am, Tuesday, 07'th Jan 2025
ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.
AbbVie cuts 2024 profit forecast on acquisition expenses
04:46pm, Monday, 06'th Jan 2025
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs.
The Smartest Dividend Stocks to Buy With $500 Right Now
05:45am, Monday, 06'th Jan 2025
Want to make a lot of money in the stock market without lots of stress? Buy and hold well-established companies that pay and increase dividends year after year.
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
04:17am, Monday, 06'th Jan 2025
When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields.
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
05:19am, Saturday, 04'th Jan 2025
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constan
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
08:00am, Friday, 03'rd Jan 2025
NORTH CHICAGO, Ill. , Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
07:39am, Friday, 03'rd Jan 2025
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
03:46am, Friday, 03'rd Jan 2025
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
